{"product_id":"handbook-of-psychiatric-drugs-isbn-9780470028216","title":"Handbook of Psychiatric Drugs","description":"The \u003cb\u003e\u003ci\u003eHandbook of Psychiatric Drugs\u003c\/i\u003e\u003c\/b\u003e is a comprehensive, clear, concise and quick reference to psychiatric drug therapies, designed to guide the clinician on the selection and implementation of treatment for mental illness.  \u003cp\u003eEach chapter is organised by drug class and follows a standard format for ease of use. Concise sections on pharmacology and indications for use are followed by detailed information on drug selection, initiation and maintenance of treatment and withdrawal. Adverse effects, contraindications and drug interactions are also reviewed in detail, along with issues such as treatment resistance and treatment evaluation.\u003c\/p\u003e \u003cp\u003eA handy pocket-sized drug reference, the \u003cb\u003e\u003ci\u003eHandbook of Psychiatric Drugs\u003c\/i\u003e\u003c\/b\u003e makes it easy to keep up-to-date with new developments. It is an invaluable resource for all clinicians who use psychiatric drugs to treat medical and psychiatric illness, and an informative read for all those with an interest in the subject.\u003c\/p\u003e  \u003cb\u003ePreface.\u003c\/b\u003e  \u003cp\u003e\u003cb\u003eAcknowledgements.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eDisclaimer.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 Antipsychotic Drugs.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eIntroduction.\u003c\/p\u003e \u003cp\u003ePharmacology.\u003c\/p\u003e \u003cp\u003eChemistry.\u003c\/p\u003e \u003cp\u003eMechanism of Action.\u003c\/p\u003e \u003cp\u003ePharmacokinetics.\u003c\/p\u003e \u003cp\u003eIndications for Use of Antipsychotic Drugs.\u003c\/p\u003e \u003cp\u003eDrug Selection and Initiation of Treatment.\u003c\/p\u003e \u003cp\u003eDrug Selection for the Treatment of Schizophrenia.\u003c\/p\u003e \u003cp\u003eEffects of Antipsychotic Agents on Symptoms of Schizophrenia.\u003c\/p\u003e \u003cp\u003eDrug Selection for the Treatment of Bipolar Disorder.\u003c\/p\u003e \u003cp\u003eDrug Selection for the Treatment of Major Depression With Psychotic Features.\u003c\/p\u003e \u003cp\u003eDrug Selection for the Treatment of Delusional Disorder.\u003c\/p\u003e \u003cp\u003eDrug Selection for the Treatment of Delirium.\u003c\/p\u003e \u003cp\u003eDrug Selection for the Treatment of Psychosis and Agitation Associated with Dementia.\u003c\/p\u003e \u003cp\u003eDrug Selection for the Treatment of Mental Retardation and Developmental Disorders.\u003c\/p\u003e \u003cp\u003eDrug Selection for Huntington’s Disease and Tourette’s Disorder.\u003c\/p\u003e \u003cp\u003eSubstance-induced Psychoses.\u003c\/p\u003e \u003cp\u003eAdverse Effects of Antipsychotics.\u003c\/p\u003e \u003cp\u003eAcute Extrapyramidal Side Effects (Dystonia, Parkinsonism, Akathisia).\u003c\/p\u003e \u003cp\u003eTardive Dyskinesia and Other Tardive Syndromes.\u003c\/p\u003e \u003cp\u003eNeuroleptic Malignant Syndrome.\u003c\/p\u003e \u003cp\u003eEndocrine and Sexual Effects.\u003c\/p\u003e \u003cp\u003eMetabolic Effects.\u003c\/p\u003e \u003cp\u003eCardiovascular Effects.\u003c\/p\u003e \u003cp\u003eGastrointestinal Effects.\u003c\/p\u003e \u003cp\u003eHepatic Effects.\u003c\/p\u003e \u003cp\u003eHematological Effects.\u003c\/p\u003e \u003cp\u003eOther Side Effects.\u003c\/p\u003e \u003cp\u003eDrug Interactions and Antipsychotic Agents.\u003c\/p\u003e \u003cp\u003eAntipsychotic Medications and Pregnancy.\u003c\/p\u003e \u003cp\u003eAdditional Reading.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 Antidepressants.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eIntroduction.\u003c\/p\u003e \u003cp\u003ePharmacology.\u003c\/p\u003e \u003cp\u003eMechanisms of Action.\u003c\/p\u003e \u003cp\u003ePharmacokinetics.\u003c\/p\u003e \u003cp\u003eIndications for Use of Antidepressants.\u003c\/p\u003e \u003cp\u003ePanic Disorder (PD).\u003c\/p\u003e \u003cp\u003eObsessive–Compulsive Disorder (OCD).\u003c\/p\u003e \u003cp\u003eGeneralized Anxiety Disorder (GAD).\u003c\/p\u003e \u003cp\u003eSocial Phobias and Posttraumatic Stress Disorder (PTSD).\u003c\/p\u003e \u003cp\u003eBulimia.\u003c\/p\u003e \u003cp\u003eAnorexia Nervosa.\u003c\/p\u003e \u003cp\u003eBody Dysmorphic Disorder (BDD).\u003c\/p\u003e \u003cp\u003ePremenstrual Dysphoria (PMDD).\u003c\/p\u003e \u003cp\u003eChildhood Disorders.\u003c\/p\u003e \u003cp\u003eOther Psychiatric Disorders.\u003c\/p\u003e \u003cp\u003eOther Medical Conditions.\u003c\/p\u003e \u003cp\u003eDrug Selection and Initiation of Treatment for Major Depression.\u003c\/p\u003e \u003cp\u003eSpecial Considerations in the Selection of an Antidepressant.\u003c\/p\u003e \u003cp\u003eInitiation of Treatment.\u003c\/p\u003e \u003cp\u003eTherapeutic Drug Monitoring.\u003c\/p\u003e \u003cp\u003eEarly, or Pre-response, Period.\u003c\/p\u003e \u003cp\u003eResponse, or Acute Treatment, Period.\u003c\/p\u003e \u003cp\u003eTreatment of Partially Responsive and Nonresponsive Patients.\u003c\/p\u003e \u003cp\u003eAntidepressant Augmentation.\u003c\/p\u003e \u003cp\u003eChanging to a New Agent.\u003c\/p\u003e \u003cp\u003eContinuation and Maintenance Periods, and Discontinuation.\u003c\/p\u003e \u003cp\u003eSide Effects.\u003c\/p\u003e \u003cp\u003eAnticholinergic Effects.\u003c\/p\u003e \u003cp\u003eAutonomic Effects.\u003c\/p\u003e \u003cp\u003eNeurologic Effects.\u003c\/p\u003e \u003cp\u003eWeight Gain.\u003c\/p\u003e \u003cp\u003eGastrointestinal Symptoms.\u003c\/p\u003e \u003cp\u003eSexual Dysfunction.\u003c\/p\u003e \u003cp\u003eCardiac Conduction.\u003c\/p\u003e \u003cp\u003eSuicide Risk.\u003c\/p\u003e \u003cp\u003eAllergic and Hematologic Effects.\u003c\/p\u003e \u003cp\u003eOther Effects.\u003c\/p\u003e \u003cp\u003eCentral Serotonergic Syndrome.\u003c\/p\u003e \u003cp\u003eMonoamine Oxidase Inhibitors.\u003c\/p\u003e \u003cp\u003eDrug Interactions.\u003c\/p\u003e \u003cp\u003eTricyclic Antidepressants.\u003c\/p\u003e \u003cp\u003ePharmacokinetic Effects.\u003c\/p\u003e \u003cp\u003eMonoamine Oxidase Inhibitors.\u003c\/p\u003e \u003cp\u003eSerotonin Reuptake Inhibitors.\u003c\/p\u003e \u003cp\u003eOther Second-Generation Antidepressants.\u003c\/p\u003e \u003cp\u003eThird-Generation Antidepressants.\u003c\/p\u003e \u003cp\u003eSummary.\u003c\/p\u003e \u003cp\u003eRecommendations for the Use of Antidepressants.\u003c\/p\u003e \u003cp\u003eAdditional Reading.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 Mood Stabilizers.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eIntroduction.\u003c\/p\u003e \u003cp\u003ePharmacology.\u003c\/p\u003e \u003cp\u003eChemistry.\u003c\/p\u003e \u003cp\u003eMechanism of Action.\u003c\/p\u003e \u003cp\u003ePharmacokinetics.\u003c\/p\u003e \u003cp\u003eIndications.\u003c\/p\u003e \u003cp\u003eDrug Selection and Initiation of Treatment.\u003c\/p\u003e \u003cp\u003eAcute Mania.\u003c\/p\u003e \u003cp\u003eDrug Selection.\u003c\/p\u003e \u003cp\u003eRelative Efficacy of Different Agents.\u003c\/p\u003e \u003cp\u003eTreatment Initiation and Dose Titration.\u003c\/p\u003e \u003cp\u003eAcute Depression.\u003c\/p\u003e \u003cp\u003eDrug Selection.\u003c\/p\u003e \u003cp\u003eTreatment Initiation and Dose Titration.\u003c\/p\u003e \u003cp\u003eBreakthrough Episodes.\u003c\/p\u003e \u003cp\u003eMaintenance.\u003c\/p\u003e \u003cp\u003eRapid Cycling.\u003c\/p\u003e \u003cp\u003eCosts.\u003c\/p\u003e \u003cp\u003eAdverse Effects.\u003c\/p\u003e \u003cp\u003eDrug Interactions.\u003c\/p\u003e \u003cp\u003ePregnancy.\u003c\/p\u003e \u003cp\u003eSummary.\u003c\/p\u003e \u003cp\u003eAdditional Reading.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 Anxiolytic Drugs.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eIntroduction.\u003c\/p\u003e \u003cp\u003eA General Approach to Using Medication with Anxious Patients.\u003c\/p\u003e \u003cp\u003ePharmacology.\u003c\/p\u003e \u003cp\u003eAntidepressants.\u003c\/p\u003e \u003cp\u003eBenzodiazepines.\u003c\/p\u003e \u003cp\u003eBuspirone.\u003c\/p\u003e \u003cp\u003eBeta-Blocker Medications.\u003c\/p\u003e \u003cp\u003eAnticonvulsants.\u003c\/p\u003e \u003cp\u003eAntipsychotics.\u003c\/p\u003e \u003cp\u003eIndications for Use.\u003c\/p\u003e \u003cp\u003eAntidepressants.\u003c\/p\u003e \u003cp\u003eBenzodiazepines.\u003c\/p\u003e \u003cp\u003eBuspirone.\u003c\/p\u003e \u003cp\u003eBeta-blocker Medications.\u003c\/p\u003e \u003cp\u003eAnticonvulsants.\u003c\/p\u003e \u003cp\u003eAntipsychotics.\u003c\/p\u003e \u003cp\u003eAugmentation\/Adjuvant Treatments.\u003c\/p\u003e \u003cp\u003eDrug Selection, Dose, and Initiation of Treatment.\u003c\/p\u003e \u003cp\u003eSide Effects.\u003c\/p\u003e \u003cp\u003eDrug Interactions.\u003c\/p\u003e \u003cp\u003eContraindications and Special Precautions.\u003c\/p\u003e \u003cp\u003eSummary.\u003c\/p\u003e \u003cp\u003eAdditional Reading.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 Sedative–Hypnotic Agents.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eIntroduction.\u003c\/p\u003e \u003cp\u003eDiagnosis.\u003c\/p\u003e \u003cp\u003eTreatment Options.\u003c\/p\u003e \u003cp\u003eNon-prescription Agents.\u003c\/p\u003e \u003cp\u003ePrescription Medications.\u003c\/p\u003e \u003cp\u003ePharmacology.\u003c\/p\u003e \u003cp\u003eBenzodiazepines.\u003c\/p\u003e \u003cp\u003eChloral Hydrate.\u003c\/p\u003e \u003cp\u003eZolpidem.\u003c\/p\u003e \u003cp\u003eZaleplon.\u003c\/p\u003e \u003cp\u003eEszopiclone.\u003c\/p\u003e \u003cp\u003eRamelteon.\u003c\/p\u003e \u003cp\u003eDrug Selection.\u003c\/p\u003e \u003cp\u003eOther Prescription Hypnotics.\u003c\/p\u003e \u003cp\u003eTreatment Implementation.\u003c\/p\u003e \u003cp\u003eAdverse Effects.\u003c\/p\u003e \u003cp\u003eBenzodiazepines.\u003c\/p\u003e \u003cp\u003eChloral Hydrate.\u003c\/p\u003e \u003cp\u003eZolpidem.\u003c\/p\u003e \u003cp\u003eZaleplon.\u003c\/p\u003e \u003cp\u003eEszopiclone.\u003c\/p\u003e \u003cp\u003eRamelteon.\u003c\/p\u003e \u003cp\u003eDrug Interactions and Special Precautions.\u003c\/p\u003e \u003cp\u003eSummary.\u003c\/p\u003e \u003cp\u003eAdditional Reading.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 Psychostimulants.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eIntroduction.\u003c\/p\u003e \u003cp\u003ePharmacology.\u003c\/p\u003e \u003cp\u003eChemistry.\u003c\/p\u003e \u003cp\u003eMechanism of Action.\u003c\/p\u003e \u003cp\u003ePharmacokinetics.\u003c\/p\u003e \u003cp\u003eIndications and Contraindications.\u003c\/p\u003e \u003cp\u003eDrug Selection.\u003c\/p\u003e \u003cp\u003eTreatment Initiation and Dose Titration.\u003c\/p\u003e \u003cp\u003eTreatment Evaluation.\u003c\/p\u003e \u003cp\u003eMaintenance Treatment.\u003c\/p\u003e \u003cp\u003eTreatment Resistance.\u003c\/p\u003e \u003cp\u003eEffects of Treatment on Symptoms.\u003c\/p\u003e \u003cp\u003eADHD in Adults.\u003c\/p\u003e \u003cp\u003eAlternative Preparations to the Standard Stimulant Medications.\u003c\/p\u003e \u003cp\u003eNarcolepsy.\u003c\/p\u003e \u003cp\u003eOther Indications.\u003c\/p\u003e \u003cp\u003eCosts.\u003c\/p\u003e \u003cp\u003eAdverse Effects.\u003c\/p\u003e \u003cp\u003eDrug Interactions.\u003c\/p\u003e \u003cp\u003eSummary.\u003c\/p\u003e \u003cp\u003eAdditional Reading.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Cognitive Enhancers and Treatments for Alzheimer’s Disease.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eIntroduction.\u003c\/p\u003e \u003cp\u003ePharmacology.\u003c\/p\u003e \u003cp\u003eMechanism of Action.\u003c\/p\u003e \u003cp\u003ePharmacokinetics.\u003c\/p\u003e \u003cp\u003eIndications.\u003c\/p\u003e \u003cp\u003eDrug Selection.\u003c\/p\u003e \u003cp\u003eTreatment Initiation.\u003c\/p\u003e \u003cp\u003eMaintenance Treatment.\u003c\/p\u003e \u003cp\u003eTreatment Evaluation.\u003c\/p\u003e \u003cp\u003eAdverse Effects.\u003c\/p\u003e \u003cp\u003eCholinesterase Inhibitors.\u003c\/p\u003e \u003cp\u003eDrug Interactions.\u003c\/p\u003e \u003cp\u003eSummary.\u003c\/p\u003e \u003cp\u003eAdditional Reading.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 Drugs for Treating Substance Abuse Disorders.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eIntroduction.\u003c\/p\u003e \u003cp\u003eSyndromes Associated with Intoxication.\u003c\/p\u003e \u003cp\u003eAlcohol Intoxication.\u003c\/p\u003e \u003cp\u003eSedative–Hypnotic Intoxication.\u003c\/p\u003e \u003cp\u003eOpiate Intoxication.\u003c\/p\u003e \u003cp\u003eCocaine and Amphetamine Intoxication.\u003c\/p\u003e \u003cp\u003eIntoxication by LSD, Mescaline, MDMA (‘Ecstasy’), and Psilocybin.\u003c\/p\u003e \u003cp\u003ePhencyclidine Intoxication.\u003c\/p\u003e \u003cp\u003eDrug Treatment of Withdrawal Syndromes.\u003c\/p\u003e \u003cp\u003eAlcohol Withdrawal.\u003c\/p\u003e \u003cp\u003eWithdrawal from Sedative–Hypnotics.\u003c\/p\u003e \u003cp\u003eWithdrawal from Opiates.\u003c\/p\u003e \u003cp\u003eManagement of Withdrawal in Patients with Multiple Dependencies.\u003c\/p\u003e \u003cp\u003eAgents to Aid Relapse Prevention.\u003c\/p\u003e \u003cp\u003eMedications for Alcohol Dependence.\u003c\/p\u003e \u003cp\u003eMedications for Cocaine Dependence.\u003c\/p\u003e \u003cp\u003eMedications for Opiate Dependence.\u003c\/p\u003e \u003cp\u003eSpecial Considerations.\u003c\/p\u003e \u003cp\u003eDrug Treatments for Nicotine Dependence.\u003c\/p\u003e \u003cp\u003ePharmacotherapies for Substance Abusers with Additional Psychiatric Illness.\u003c\/p\u003e \u003cp\u003ePharmacotherapy for Specific Psychiatric Disorders.\u003c\/p\u003e \u003cp\u003eDrug Interactions in Chemical Dependency.\u003c\/p\u003e \u003cp\u003eAdditional Reading.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eIndex.\u003c\/b\u003e\u003c\/p\u003e  \"...an excellent little book...small enough that busy clinicians can easily read it cover to cover.\" (\u003ci\u003ePsychiatric Times\u003c\/i\u003e, June 2007)  \u003cp\u003e\"…a basic guide to drugs used to treat mental disorders…at a reasonable cost and in a handy format.\" (\u003ci\u003eAmerican Reference Books Annual\u003c\/i\u003e, March 2007)\u003c\/p\u003e \u003cp\u003e\"…a welcome addition…well-written, easy to use, and thorough in its coverage…psychiatry residents as well as practicing clinicians will find this a useful, quick referral source.\" (\u003ci\u003eDoody's Health Services\u003c\/i\u003e)\u003c\/p\u003e  \u003cb\u003eJeffrey Lieberman\u003c\/b\u003e is the head of the Department of Psychiatry at Columbia University.  He is a leading psychiatric drug researcher with excellent clinical, academic and publishing credentials.  \u003cp\u003e\u003cb\u003eAllan Tasman\u003c\/b\u003e Professor and Chair, Department of Psychiatry and Behavioral Sciences, University of  Louisville, USA and Past President of the APA.  He is President Elect, Pacific Rim College of Psychiatrists and active in the WPA.\u003c\/p\u003e  \u003cb\u003e\u003ci\u003eHandbook of Psychiatric Drugs\u003c\/i\u003e\u003c\/b\u003e is a comprehensive, clear, concise, quick reference to psychiatric drug therapies, designed to guide the clinician on the selection and implementation of treatment for mental illness.  \u003cp\u003eEach chapter is organised by drug class and follows a standard format for ease of use. Concise sections on pharmacology and indications for use are followed by detailed information on drug selection, initiation and maintenance of treatment and withdrawal. Adverse effects, contraindications and drug interactions are also reviewed in detail, along with issues such as treatment resistance and treatment evaluation.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e\u003ci\u003eHandbook of Psychiatric Drugs\u003c\/i\u003e\u003c\/b\u003e is an invaluable resource for all clinicians who use psychiatric drugs to treat medical and psychiatric illness.\u003c\/p\u003e","brand":"Wiley","offers":[{"title":"Default Title","offer_id":47989339881701,"sku":"NP9780470028216","price":32.0,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9780470028216.jpg?v=1761783731","url":"https:\/\/k12savings.com\/products\/handbook-of-psychiatric-drugs-isbn-9780470028216","provider":"K12savings","version":"1.0","type":"link"}